Loading...
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European thoracic oncology platform (ETOP) EMPHASIS-lung trial.
Peters, S Stahel, R Dafni, U Ponce Aix, S Massutí, B Gautschi, O Coate, L López Martín, A van Heemst, R Berghmans, T
Peters, S
Stahel, R
Dafni, U
Ponce Aix, S
Massutí, B
Gautschi, O
Coate, L
López Martín, A
van Heemst, R
Berghmans, T
Citations
Altmetric:
Abstract
Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial.
Authors
Peters, S
Stahel, R
Dafni, U
Ponce Aix, S
Massutí, B
Gautschi, O
Coate, L
López Martín, A
van Heemst, R
Berghmans, T
Meldgaard, P
Cobo Dols, M
Garde Noguera, J
Curioni-Fontecedro, A
Rauch, D
Mark, M
Cuffe, S
Biesma, B
van Henten, A
Juan Vidal, Ó
Palmero Sanchez, R
Villa Guzmán, J
Collado Martin, R
Peralta, S
Insa, A
Summers, Yvonne J
Láng, I
Horgan, A
Ciardiello, F
de Hosson, S
Pieterman, R
Groen, H
van den Berg, P
Zielinski, C
Chittazhathu Kurian Kuruvilla, Y
Gasca-Ruchti, A
Kassapian, M
Novello, S
Torri, V
Tsourti, Z
Gregorc, V
Smit, E
Stahel, R
Dafni, U
Ponce Aix, S
Massutí, B
Gautschi, O
Coate, L
López Martín, A
van Heemst, R
Berghmans, T
Meldgaard, P
Cobo Dols, M
Garde Noguera, J
Curioni-Fontecedro, A
Rauch, D
Mark, M
Cuffe, S
Biesma, B
van Henten, A
Juan Vidal, Ó
Palmero Sanchez, R
Villa Guzmán, J
Collado Martin, R
Peralta, S
Insa, A
Summers, Yvonne J
Láng, I
Horgan, A
Ciardiello, F
de Hosson, S
Pieterman, R
Groen, H
van den Berg, P
Zielinski, C
Chittazhathu Kurian Kuruvilla, Y
Gasca-Ruchti, A
Kassapian, M
Novello, S
Torri, V
Tsourti, Z
Gregorc, V
Smit, E
Description
Date
2016-12-23
Publisher
Collections
Keywords
Type
Article
Citation
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European thoracic oncology platform (ETOP) EMPHASIS-lung trial. 2016, J Thorac Oncol